Wednesday, May 13, 2020 5:51:44 PM
I'm playing a Long long game on CYRX. It's been quite good for me and I'm holding on as I see the pipeline filled with so much potential I would kick myself if I sold now only to see it up 100% within 2 years.
I have a hard time coming up with the argument to say revenue will drop in the next two years when I see what those slides. Nothing spectacular from a technical viewpoint (they have the infrastructure, that's in place), so all that's needed overall is filling the pipeline and getting products approved. In other words, it's not your typical biotech where so much brain power is needed, together with navigating the forces against you from powerful BP's, character assassination, stock manipulation. This is one is relatively simple. A bit like what Warren Buffet likes, you don't need geniuses to manage the company, the model is well established and can be managed by filling the pipeline and executing.
Ph III clinical trials have a historical success rate. For example:
"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226120/
So out of 62 Phase III, say 70% are successful, that would mean 43 approvals. Even if it drops to 30, I believe that CYRX will be quite successful.
A big picture view. (Not an advice to buy, by the way, just my humble opinion).
Best of luck with your investments!
Recent CYRX News
- Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:30:00 PM
- Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:42:22 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 05:22:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/21/2023 09:30:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/20/2023 05:15:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:19:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/15/2023 10:09:12 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 12/15/2023 10:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 11:02:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/11/2023 10:09:00 PM
- Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express • PR Newswire (US) • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:30:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:18:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:31:41 PM
- Cryoport Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/08/2023 09:05:00 PM
- Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition • PR Newswire (US) • 11/02/2023 12:30:00 PM
- Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 • PR Newswire (US) • 10/25/2023 12:30:00 PM
- Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF • PR Newswire (US) • 10/12/2023 12:30:00 PM
- Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies • PR Newswire (US) • 10/10/2023 12:30:00 PM
- Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 08:05:00 PM
- Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award • PR Newswire (US) • 09/14/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM